VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/12/22
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/22
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor PlatformGlobeNewsWire • 05/10/22
VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10thGlobeNewsWire • 05/06/22
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic DermatitisGlobeNewsWire • 04/07/22
VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid ArthritisBenzinga • 03/30/22
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid ArthritisGlobeNewsWire • 03/30/22
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/17/22
VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin DisorderBenzinga • 03/07/22
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of VitiligoGlobeNewsWire • 03/07/22
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic DermatitisGlobeNewsWire • 01/19/22
VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ DealBenzinga • 01/13/22
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access EventGlobeNewsWire • 01/03/22
Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?Zacks Investment Research • 12/13/21
VYNE Stock Price Predictions: Why One Analyst Sees VYNE Therapeutics Going to $7InvestorPlace • 12/06/21